MaxCyte, Inc. Grant of Options and PDMR Dealing (7228Y)
January 05 2024 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7228Y
MaxCyte, Inc.
05 January 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and PDMR Dealing
ROCKVILLE, MD, 5 January 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and innovative bioprocessing applications to support
innovative, cell-based research , announces that on 3 January 2024,
400,000 options of common stock in the Company ("Common Stock")
were granted to Maher Masoud, President, Chief Executive Officer
and Director of the Company pursuant to a pre-agreed arrangement in
connection with his appointment as President, Chief Executive
Officer and Director of the Company as announced on 12 December
2023.
The options granted vest 12/48th of the total grant on 2 January
2025, and 1/48th of the total shares will vest each month
thereafter on the same day of the month. The options granted have
an exercise period of 10 years from date of grant, at which time
they will expire, and have an exercise price equal to the closing
price of MaxCyte's stock on 3 January 2024, being $4.42 on the
Nasdaq Stock Exchange.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
ICR Consilium maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Maher Masoud
--------------------------------- --------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status President, CEO and Director
--------------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name MaxCyte Inc.
--------------------------------- --------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Common Stock of $0.01 each
financial instrument,
type of instrument
Identification code US57777K1060
b) Nature of the transaction Grant of options of common stock
--------------------------------- --------------------------------------
c) Price(s) and volume(s)
--------------------- ------------
Exercise Price(s) Volume(s)
--------------------- ------------
$4.42 400,000
--------------------- ------------
d) Aggregated information
- Aggregated volume 400,000
- Price $4.42
e) Date of the transaction January 3, 2024
--------------------------------- --------------------------------------
f) Place of the transaction US Stock Exchange, Nasdaq
--------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHZZGGMMDGGDZZ
(END) Dow Jones Newswires
January 05, 2024 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024
